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Background and objectives: Nephrotic syndrome (NS) represents a common disease in pediatric nephrology
typified by a relapsing and remitting course and characterized by the presence of edema that can significantly
affect the health-related quality of life in children and adolescents. The PROMIS pediatric measures were
constructed to be publically available, efficient, precise, and valid across a variety of diseases to assess patient
reports of symptoms and quality of life. This study was designed to evaluate the ability of children and adolescents
with NS to complete the PROMIS assessment via computer and to initiate validity assessments of the short forms
and full item banks in pediatric NS. Successful measurement of patient reported outcomes will contribute to our
understanding of the impact of NS on children and adolescents.
Design: This cross-sectional study included 151 children and adolescents 8-17 years old with NS from 16
participating institutions in North America. The children completed the PROMIS pediatric depression, anxiety, social-
peer relationships, pain interference, fatigue, mobility and upper extremity functioning measures using a web-based
interface. Responses were compared between patients experiencing active NS (n = 53) defined by the presence of
edema and patients with inactive NS (n = 96) defined by the absence of edema.
Results: All 151 children and adolescents were successfully able to complete the PROMIS assessment via computer.
As hypothesized, the children and adolescents with active NS were significantly different on 4 self-reported
measures (anxiety, pain interference, fatigue, and mobility). Depression, peer relationships, and upper extremity
functioning were not different between children with active vs. inactive NS. Multivariate analysis showed that the
PROMIS instruments remained sensitive to NS disease activity after adjusting for demographic characteristics.
Conclusions: Children and adolescents with NS were able to successfully complete the PROMIS instrument using a
web-based interface. The computer based pediatric PROMIS measurement effectively discriminated between
children and adolescents with active and inactive NS. The domain scores found in this study are consistent with
previous reports investigating the health-related quality of life in children and adolescents with NS. This study
establishes known-group validity and feasibility for PROMIS pediatric measures in children and adolescents with NS.
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Children with nephrotic syndrome (NS) represent a
unique patient population in pediatrics [1]. The signs and
symptoms of NS include physical changes typified by
edema that can be uncomfortable as well as alarming to
patients and families. The disease course that character-
izes NS is one of unpredictable relapse and remission, and
often treated with multiple courses of corticosteroids,
diuretics, antihypertensive medications, and intermittent
hospitalizations. In addition to the clinical measures of
disease activity, assessment of patient reported outcomes
(PRO) and health-related quality of life (HRQOL) can as-
sist in understanding how patients feel and function to
better guide clinical care and trials.
A number of disease characteristics inherent to NS in-
cluding the presence of edema, repeated corticosteroid
exposures, and the relapsing nature of NS pose particular
challenges to patient HRQOL [2]. Recent studies on the
impact of NS on HRQOL have found impairments in
social, emotional, and physical functioning [2,3]. The
worst cases of NS may progress to end stage renal disease
(ESRD). Previous studies in pediatric patients with chronic
kidney disease and ESRD have demonstrated a significant
burden on HRQOL [4,5]. Studies investigating HRQOL in
pediatric chronic kidney disease and NS have utilized a
number of different instruments, including but not limited
to the ESRD specific PedsQL 3.0™ [6], The Netherlands
Organization for Applied Scientific Research Academical
Medical Center Child Quality of Life Questionnaire [2],
the Child Health and Illness Profile - Adolescent Edition
[5], and PedsQL 4.0™ [7]. The diversity of measures used
in children younger than 18 years of age makes it difficult
to compare research findings across studies and to other
patient populations.
The Patient Reported Outcomes Measurement Informa-
tion System (PROMIS) project was established as part of
the National Institutes of Health Roadmap Initiative to
create item banks for both adults and children, which are
publically available, efficient, precise, and valid across a
variety of diseases to assess PROs (www.nihpromis.org).
In the first phase of PROMIS, 9 item banks were devel-
oped for measurement of child self-reported outcomes:
depression, anxiety, social-peer relationships, pain inter-
ference, fatigue, mobility, upper extremity, anger, and
asthma impact [8-13]. PROMIS pediatric measures were
developed using qualitative and quantitative methods
(focus groups, expert item review, cognitive interviewing,
and item administration to a large population of children
and adolescents) to create banks of items specific to se-
lected symptoms and quality of life [11,14-17] for use in
children 8 to 17 years of age [10,12,13]. PROMIS was de-
veloped in order to give researchers flexibility in selecting
items or domains that are relevant to the disease of inter-
est. The PROMIS measures have been or are currentlyunder study in several other pediatric chronic health con-
ditions including asthma, sickle cell disease, cancer,
rheumatic disease, and obesity. The intent of the PROMIS
initiative is to advance the measurement of HRQOL
symptoms and functioning by utilizing the same measures
across chronic illnesses in children and adolescents, yield-
ing knowledge through comparability of items and scores
across diverse pediatric populations. The development
and validation of the PROMIS instrument becomes par-
ticularly important in pediatric clinical research and
pediatric therapeutics as PROs are acceptable clinical trial
endpoints to the Food and Drug Administration [18].
This study was designed to evaluate the ability of
children and adolescents with nephrotic syndrome to
complete the PROMIS assessment via computer and to
initiate validity assessments of PROMIS pediatric mea-
sures in NS. We hypothesized that the children and ado-
lescents with NS would be able to complete the computer
based items and that the PROMIS scores would show
worse functioning in children with active NS compared to
children without active NS.
Methods
This cross-sectional study was conducted by the Midwest
Pediatric Nephrology Consortium (MWPNC) and included
151 pediatric patients with NS from 16 participating mem-
ber institutions. Each site obtained individual institutional
Institutional Review Board approval. Parents and children
gave informed consent and assent respectively, prior to
performing the study.
Training study team members
Personnel at each site (investigators and study coordina-
tors) received web-based training in study procedures; the
study operations manual was a reference tool for study con-
duct, quality control, and recruitment. Ongoing education
of site personnel occurred during investigator and coordin-
ator conference calls.
Eligibility
Consistent with the target age for the PROMIS pediatric
item banks, the PROMIS NS cohort study included chil-
dren 8-17 years. The NS eligibility criteria included pres-
ence or history of proteinuria (>2+ urinalysis or urine
protein/creatinine ratio >2 g/g) and/or a kidney biopsy
that confirmed a NS-inducing condition. Another eligibil-
ity criterion was the ability to speak and read English. Ex-
clusion criteria included co-existing medical, psychiatric,
or cognitive impairments that would prevent the patient
from answering the computer administered questionnaire.
Study procedures
Both the parent and child completed questionnaires. The
parent completed the Family and Medical Information
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cation level, socioeconomic, and disease specific ques-
tions. Child and disease characteristics included: gender,
age, race, ethnicity, disease etiology, dialysis, transplant,
co-existing conditions, hospitalizations in the previous 6 -
months (hospitalization history), surgery in the previous
12 months, number of medications, corticosteroid ther-
apy, self-rated edema status, and the guardian’s perception
of the child’s weight status (underweight, healthy weight,
or overweight). Clinical data such as diagnosis, kidney
function represented by estimated glomerular filtration
rate (eGFR), chronic kidney disease stage with a higher
stage equivalent to poorer kidney function [19], and ster-
oid therapy resistance in NS patients were abstracted from
medical records by the local study team. Disease activity
was defined as presence of edema at the time of the study
visit. Edema was classified as mild or moderate when the
feet, ankles, or legs were involved and severe edema was
defined to include the abdomen or whole body. Active
edema was used in analyses. The GFR was estimated by the
classic Schwartz method that was available prior to publica-
tion of the updated Schwartz equation [20]. Chronic kidney
disease was defined based on estimated GFR (ml/min/1.73
meters squared) as follows; stage I (> 90), stage II (60-89),
stage III (30-59), stage IV (15-29), and stage V (< 15 or dia-
lysis dependence).
The children completed the PROMIS pediatric depres-
sion, anxiety, social-peer relationships, pain interference, fa-
tigue, mobility, and upper extremity functioning domains
using a web-based interface. The definitions of the domains
are located at http://www.nihpromis.org/measures/domain-
framework1. All of these PROMIS items use the context
statement “In the past 7 days.” Responses included 5 op-
tions ranging from “never” to “almost always” in the major-
ity of domains and from “with no trouble” to “not able to
do” for the physical functioning measures. Each PROMIS
pediatric domain generates a T-score with a mean of 50
and a standard deviation of 10. The mean of 50 reflects the
calibration population and does not represent the general
population or other specific group. Higher scores indicate
more of the measured symptom, thus signifying worse
symptoms of depression, anxiety, fatigue, and pain interfer-
ence and better functioning for mobility, upper extremity,
and peer relationships. These measures have been previ-
ously tested in a large group of children and adolescents,
confirming their unidimensionality and the extent to which
each item is associated with the measured variable (www.
assessmentcenter.net) [8,10-13]. PROMIS pediatric mea-
sures have consistently achieved a reliability of 0.85 or
greater over a range of 2 to 4 standard deviations with the
short forms [8,10,12,13]. Short forms include 8 items for all
domains except fatigue (10 items) and anger (6 items).
In order to decrease the response burden, a sampling
plan was devised and is summarized in Table 1.Participants were randomly assigned to one of two study
arms by the PROMIS Assessment Center after they were
registered to take the survey. In total, participants com-
pleted 70 to 90 questions over 30 to 40 minutes using this
strategy.
When full bank data were collected, a short-form
score was also calculated. The full item bank and short
form domain scores for depression, anxiety, pain inter-
ference, fatigue, upper extremity functioning, and mobil-
ity were highly correlated, Pearson’s R ranging 0.95-1.0.
Consequently, the short form results for all domains are
presented here.
Statistical analysis
Descriptive summary statistics were calculated as frequen-
cies and percentages for demographic and clinical charac-
teristics and as means and standard deviations for eGFR
scores and number of medications. Mean scores as well as
standard deviations were calculated for each of the 7 do-
mains by full bank and short form. To assess the associ-
ation of full bank and short-form scores, Pearson’s
correlations were calculated where applicable. Known-
group validity [21] was assessed for each PROMIS domain
by testing whether the scores were different between the
two disease activity groups (active vs. inactive). Univariate
and multivariate analyses were conducted using the short-
form mean scores. Multivariate analysis included covari-
ates, active disease status, age, race, gender, ethnicity, and
guardian education level. Mean domain scores were com-
pared by child characteristics and disease status using t-
tests for variables with 2 levels and ANOVA for variables
with more than 2 levels. Comparisons were performed
using non-parametric Wilcoxon test and Kruskal-Wallis
test when appropriate for variables that were not normally
distributed. Cohen’s d effect sizes were calculated, and
interpreted using standard definitions of “small” where ab-
solute effect size (AES) value |d| = 0.0-0.4, “medium”
where |d| = 0.5-0.7 and “large” where |d| ≥ 0.8 [22]. Simul-
taneous regression analyses were conducted for the 7 do-
main scores.
Although missing clinical data were minimal, two pa-
tient reported outcome (PRO) domain scores (Pain
Interference and Fatigue) have responses from 50% of
patients by design of this study. Note that the other 5
PRO scores are available for the entire cohort. We ap-
plied the Expectation-Maximization (EM) algorithm [23]
to handle missing outcomes in the simultaneous regres-
sion of the 7 PRO scores, which has been implemented
in MATLAB package mvregress. The EM algorithm is
known as a very powerful statistical approach to carrying
out statistical analyses with missing data because in this
algorithm the distribution of missing data, instead of im-
puted values, are utilized in the estimation and infer-
ence. With the exception of the mvregress simultaneous
Table 1 PROMIS domain randomization scheme
Form administered Pain interference* Fatigue* Social-peer Depression Anxiety Mobility Upper extremity
functioning
None 50% 50%
Short form 100% 50% 50% 50% 50%
Full Item bank 50% 50% 50% 50% 50% 50%
*The randomization scheme allocated participants to either the full item bank for the Pain domain or the full item bank for the Fatigue domain.
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conducted using SAS v9.2.
Results
Child demographic, disease characteristics, and guardian
demographic characteristics are presented in Table 2.
There were 151 children with NS enrolled. The majority
of guardians who completed the demographic items
were parents (n = 138, 91%). Edema was present in 35%
(N = 53) of patients, with 32 patients demonstrating mild
to moderate edema and 21 patients showing severe
edema. Fifty percent (N = 75) of the patients were on
steroid therapy at the time of study, and 36% (N=54) of
patients required hospitalization in the 6 months prior
to the study. Fifty-eight (38%) had steroid sensitive NS,
77 (51%) steroid resistant disease, and steroid resistance
status was unknown for 16 (11%). Eighty-eight (58%) pa-
tients had CKD stage 1, 36 (24%) had CKD stage II-IV, 7
(5%) had CKD stage V, and 19 (13%) were renal transplant
patients. Sixty-five (43%) had other parent-reported health
conditions, with asthma (11%), overweight (9%), and pre-
mature birth (9%) being the most common.
Feasibility
Four children (2.6%) had missing scores for at least one
of the PROMIS domains. Four of 151 (2.6%) ended the
survey early, so that measures at the beginning of ad-
ministration were completed but responses were missing
at the end of the administration. Thirty-three of 151
(22%) skipped one or more PROMIS questions within
the administration. A missing value analysis examined
patterns of missingness by the type of measure adminis-
tered (full bank or short form), by domain, and by pa-
tient age. The domains were administered in random
order and no pattern of missingness was observed.
Descriptive results
The mean scores for the PROMIS domains ranged from
43.9 (fatigue) to 52.5 (upper extremity functioning).
There were no differences in the PROMIS measures by
gender. However, the PROMIS fatigue domain scores
were associated with race (p =0.007), and the social-peer
relationship scores were worse in children of Hispanic
ethnicity compared to those not in the Hispanic ethnic
group (p = 0.02).Validity
As hypothesized, mean scores for several PROMIS do-
mains differed between the NS active and NS inactive
groups. Children and adolescents with active NS had sig-
nificantly worse scores than participants with inactive NS
on 4 of the 8 measures, including anxiety, pain interfer-
ence, fatigue, and mobility (Effect Sizes 0.56-0.79). The
two groups did not differ on upper extremity functioning,
depression, and social-peer relationships in bivariate ana-
lysis (Table 3). An analysis of children who were steroid
resistant compared with those who were steroid respon-
sive revealed that the PROMIS Social-Peer Relationships
domain was 3 points worse on average in children with
steroid resistant NS (p = 0.04). The remaining domains
were not significantly different.
Simultaneous regression models
Regression analysis of all 7 domain scores with covariates
of interest, including NS disease activity, gender, age, eth-
nicity, guardian education, and race, was conducted. This
method enables us to borrow information across the
PROMIS domain scores. To address the challenge of the
50% administration scheme for 3 domain scores, the EM
algorithm was used to derive estimates and p values. Re-
sults of the simultaneous regression are reported in
Table 4. Overall, 4 PROMIS domains, including anxiety,
pain interference, fatigue, and mobility, were sensitive to
the marker of active NS. Children with active NS on aver-
age had about a 6 point worse score for anxiety and pain
interference, a 9 point worse score for fatigue, and a 5
point worse score for mobility (p = 0.001, p = 0.01, p <
0.001, and p < 0.001, respectively). There was no evidence
for gender differences over the 7 PROMIS domains. Child
age was found to be associated with upper extremity func-
tioning scores, such that older children had better upper
extremity functioning (p < 0.001). Hispanic ethnicity was
predictive of worse social-peer relationship (p =0.003),
upper extremity functioning (p = 0.05) and mobility (p =
0.03) scores. Children whose guardians had higher educa-
tion reported lower (better) pain interference scores (p =
0.006). Black children reported higher pain interference
scores compared with white children (p = 0.04). The pain
interference scores of Asian children were not different. A
sensitivity analysis was performed with the exclusion of
children who had CKD stage V or renal transplants. There
were 120 patients included in this analysis and the analysis
Table 2 PROMIS pediatric nephrotic syndrome cohort
Child demographics N = 151
n (%)
Male 79 (52.2)
Age (yrs)
8-12 62 (41.1)
13-17 89 (58.9)
Race
White 74 (49.0)
Black 53 (35.1)
Asian 9 (5.9)
Other, Multiple Races 14 (9.3)
Ethnicity
Non-Hispanic 141 (93.4)
Hispanic 9 (5.9)
Edema Status
None 96 (63.6)
Mild/moderate 32 (21.2)
Severe 21 (13.9)
eGFR (n), Mean, (SD)** (n = 144), 95 (47)
Co-Existing conditions (#)
None 86 (56.9)
One 43 (28.5)
≥ Two 22 (14.6)
Co-Existing conditions:***
Asthma 17 (11.2)
ADD/ADHD 12 (7.9)
Mental Disorders 11 (7.3)
Overweight 14 (9.3)
Premature birth 14 (9.3)
Rheumatic disease 8 (5.3)
Hospitalization history
Yes 54 (35.7)
Surgical History
Yes 43 (28.5)
# of daily medications, Mean(SD)) 4.4 (3.4)
Steroid Therapy
None 74 (49.0)
Alternating day 28 (18.6)
Daily or more than once/day 47(31.1)
Guardian Demographics
Relationship to Child
Parent 138 (91.4)
Grandparent 5 (3.3)
Guardian or Other 7 (4.6)
Education Level
Table 2 PROMIS pediatric nephrotic syndrome cohort
(Continued)
< High school 15 (9.9)
High school degree/GED 38 (25.2)
Some college/technical degree 55 (36.4)
College degree or more 42 (27.8)
** eGFR = estimated glomerular filtration rate.
*** Parents reported more than 1 condition; many other conditions in lower
frequency (<3%) than listed conditions.
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cant compared to the full model with only minimal
changes in the magnitudes of the differences in domain
scores (data not shown).
Confirmatory analysis was conducted using data avail-
able as collected to evaluate if missing data impacted the
results of the simultaneous regression. Simultaneous re-
gression of the 5 PROMIS domain scores completed by all
participants had similar results; anxiety and mobility were
sensitive to disease activity. In individual regression mo-
dels for the remaining 2 domains, results were also similar
to the simultaneous regression, where disease status was
predictive of domain scores for pain interference and fa-
tigue. However, race and ethnicity were not found to be
significant predictors of anxiety, upper extremity function-
ing, mobility, or pain interference.
Discussion
We report the largest study to date evaluating PRO in
children with NS. This North American multi-center
study sought to evaluate known-group validity of the
PROMIS pediatric measures with a large group of chil-
dren with NS as an exemplar chronic health condition.
Children with NS were able to complete the PROMIS
instrument using a web-based interface. This study dem-
onstrated that the PROMIS domains were responsive to
NS disease activity using the presence or absence of
edema as an indicator of active disease. Children with
active NS demonstrated worse functioning in the do-
mains of anxiety, pain interference, fatigue, and mobility
when compared to children with inactive disease. These
differences were in the domains and expected direction
for children affected by active NS.
The PROMIS instruments have been created through
a National Institutes of Health initiative to improve the
assessment of PROs [24]. Previously, most PRO research
instruments utilized classical test theory in their devel-
opment, but the PROMIS instruments were developed
using item response theory [8]. This design allows for
broader characterization of a number of domains af-
fected by disease and increased flexibility for researchers
to adapt PRO measures to their studies [8]. PROMIS
provides researchers with a potentially invaluable tool to
measure the impact of pediatric diseases using PROs. A
Table 3 PROMIS domain scores by presence of edema for children with NS
Overall Edema
Yes No
n Mean (SD) n Mean (SD) n Mean (SD) Effect size |d|
Depression 148 46 (10.8) 52 48 (12.4) 94 45 (9.8) 0.31
Anxiety*,† 151 46 (11.5) 53 50 (13.0) 96 44 (9.9) 0.56
Peer Relationships 151 50 (10.4) 53 48 (10.8) 96 51 (10.2) 0.27
Pain Interference*,† 82 47 (11.1) 33 51 (10.6) 49 45 (10.9) 0.59
Fatigue*,† 68 44 (11.8) 20 50 (13.7) 46 42 (10.1) 0.79
Upper Extremity Functioning 149 53 (7.0) 52 53 (6.9) 95 53 (7.1) 0.01
Mobility*,† 150 52 (8.1) 52 49 (9.5) 96 54 (6.9) 0.59
*p < .05 as measured by T-statistic, † p < .05 as measured by Wilcoxon test.
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als is the strength of standardized measures in repeated
administration that accounts for normative developmen-
tal changes while maintaining scores on the same metric.
Currently, researchers can use PROMIS to study the im-
pact of disease characteristics and treatments in pediatrics
in the PRO domains of depression, anxiety, social-peer
relationships, pain interference, fatigue, mobility, upper
extremity, and anger as part of any clinical trial [8-13]. In
comparison to existing pediatric quality of life measures,
PROMIS offers more specific measurement of general
health domains, but also the flexibility of using various
short forms or computerized adaptive testing that all re-
port on the same metric. For example, as noted in our
study, scores using the short forms were nearly identical
to scores using the entire item banks. The PROMIS
pediatric measures have the additional benefit of being
publically available. As part of the pediatric validation
process, the PROMIS instruments are currently being
studied in asthma, sickle cell disease, cancer, rheumaticTable 4 Results of simultaneous regression model
Depression Anxiety Social-peer
relationships in
Estimate (SE) Estimate (SE) Estimate (SE) Est
Intercept 41 (7.3) 40 (7.3) 61 (6.8)
Gender −1.0 (1.8) −0.1 (1.8) 1.3 (1.7) −
Current age −0.2 (0.3) −0.2 (0.3) 0.2 (0.3) −
Ethnicity 8.3 (5.0) 6.4 (4.9) −13.3 (4.5)*
Active
Edema
3.3 (1.9) 6.3 (1.9)* −3.1 (1.8)
Guardian
education
−0.5 (1.0) −1.0 (1.0) 0.3 (0.9) −
Black −0.3 (2.0) 4.0 (2.0) −3.1 (1.9)
Asian 0.8 (3.8) 1.2 (3.9) −3.1 (3.6)
Mixed or
Other Race
−0.1 (3.5) −2.2 (3.6) 1.3 (3.3) −
*p < .05.disease, obesity, chronic kidney disease, and NS. We
present data that show the PROMIS instruments detect
the impact of NS activity on pediatric patients.
The long-term impacts of childhood kidney disease have
been addressed in longitudinal studies involving children.
In children initiating dialysis, psychological problems have
been identified and often persist into adulthood [25,26].
Recent studies have provided some insight into the fact
that children with NS are vulnerable to challenges in their
HRQOL in areas including physical, school, emotional,
and social functioning [2,3]. Ruth and colleagues showed
that severity of illness in steroid responsive NS as deter-
mined by steroid dependence or cyclophosphamide treat-
ment was associated with worse physical and emotional
well-being [2]. These studies were relatively small in na-
ture. We extend these by reporting the largest multi-
center study to date evaluating PROs in children with NS.
Previous studies focused on chronic disease characteris-
tics, but have not evaluated the impact of acute disease
activity (edema) that may provide specific burden toPain
terference
Fatigue Upper extremity
functioning
Mobility
imate (SE) Estimate (SE) Estimate (SE) Estimate (SE)
52 (8.5) 32 (11.6) 45 (4.3) 61 (5.2)
1.3 (2.2) −1.5 (2.6) 0.2 (1.1) −0.1 (1.3)
0.5 (0.4) 0.3 (0.5) 1.0 (0.2)* −0.01 (0.2)
6.1 (5.3) 5.6 (8.4) −5.7 (2.9)* −7.5 (3.4)*
5.6 (2.3)* 9.5 (2.8)* 0.3 (1.1) −5.0 (1.4)*
3.8 (1.1)* −0.04 (1.6) 0.1 (0.6) 0.6 (0.7)
5.1 (2.4)* 2.6 (3.0) −0.7 (1.2) 0.1 (1.4)
7.5 (4.3) 8.6 (6.2) −0.9 (2.3) −2.4 (2.7)
2.0 (3.9) 9.3 (6.1) 0.3 (2.1) 2.4 (2.5)
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the PROMIS instrument was sensitive to disease activity,
specifically edema, on the PROs that previous research
has demonstrated are affected by NS. We show that chil-
dren with active NS have significantly worse scores in the
domains of pain interference, anxiety, fatigue, and mobility
relative to those children in remission.
Edema represents one of the most visibly evident symp-
toms of NS. Patients with NS are prone to edema as their
disease process relapses or proves resistant to available
therapies. In those with NS, edema is often the only overt
sign of disease activity, but does not necessarily reflect
disease progression. The impact of edema on patients in-
cludes altered physical appearance, mobility challenges, and
pain. The PROMIS instrument yielded PRO data that are
consistent with previous reports showing that children with
NS are vulnerable in the areas of emotional well-being and
mobility [2,3,5,7]. Previous reports have not evaluated the
impact of specific markers of disease activity such as edema
and their impact on PRO data. We extend the literature by
demonstrating that patients with active NS have an in-
creased burden in the domains of pain interference, anxiety,
fatigue, and mobility relative to children in remission. This
finding is strengthened by the fact that our comparative pa-
tient population was children with inactive NS, whereas
previous studies utilized healthy controls. It is understand-
able that children with active NS would have issues with
pain interference, fatigue, and mobility as the presence of
edema can directly contribute to these physical attributes.
The increased burden of anxiety symptoms may reflect the
loss of disease control in the presence of edema. Con-
versely, the domains of depression, social-peer relation-
ships, and upper extremity functioning were not different
between the disease activity strata.
The PROMIS measures performed as we had antici-
pated in their ability to distinguish differences in PROs
in individuals with active NS. Furthermore, our observed
relationships between patient demographics and PROs
are consistent with previous published reports in chil-
dren with kidney disease and other chronic diseases. We
describe that gender does not influence the outcomes of
PROs in children with NS. This is consistent with previ-
ous reports and the recent findings of Gerson et al in
their descriptions of children with mild to moderate
chronic kidney disease [7,27], indicating the strength of
the instrument. Our findings regarding the pain interfer-
ence domain are consistent with a recent investigation
into health-related quality of life utilizing the PROMIS
instrument in children with cancer that showed Black
children had an increased burden of pain interference
[28]. This finding has not been previously described in
children and adolescents with NS.
A potential limitation of this study is that it utilized an
internal comparative patient population rather than healthycontrols. However, this design allowed us to demonstrate
the strength of the PROMIS instrument in that it can de-
tect clinically meaningful differences within a patient popu-
lation with a range of disease severity. The PROMIS
pediatric self-report instruments are limited to ages 8-17.
A parent proxy-report instrument is currently being vali-
dated for ages 5 to 17. At the time of this study, only an
English version of the PROMIS pediatric instruments was
available. Consequently, this study included only children
with English literacy. Lastly, this study was cross-sectional
and does not document longitudinal changes. A longitu-
dinal study validating the responsiveness of the PROMIS
measures in patients with NS during episodes of relapse
and remission is currently underway.
Specific strengths of this study include the inclusion of
patients from a wide variety of participating centers across
North America. This represents one of the broadest pa-
tient samplings studying PROs in children with NS and
supports the potential generalizability of these results.
This study suggests possible strengths and limitations
of the PROMIS instrument for children with NS. The in-
strument allows the assessment of factors that are im-
portant from the patient perspective but which may not
receive due attention in the research or office setting.
The availability of the instrument in a web-based format
allows the collection of data in home and office settings
for ease of administration. Auto scoring functions may
facilitate the timely review and integration of the most
concerning areas if implemented within the clinical care
environment. This study suggests that domains of anx-
iety, pain, fatigue, and mobility but not depression
change with disease status. This study also demonstrates
the consistent results from long or short forms. As the
PROMIS measures were developed to allow the selection
of domains of relevance to a particular population, the
number of domains and items selected for use in research
or clinical settings can be tailored to minimize response
burden. Limitations of the instrument most relevant to
pediatric NS are the minimum age for self-report of 8 years
and a lack of multiple language versions (at this time,
PROMIS has English and Spanish versions only). Incident
pediatric NS affects all ages but a disproportionate num-
ber affects children under the age of 5 years. The absence
of self-report below age 8 years and absence of parent
proxy report for children less than 5 years is a gap that re-
quires attention if PROMIS is to gain widespread imple-
mentation across the affected population.
Conclusion
Children and adolescents with NS were able to success-
fully complete the PROMIS measures using a computer-
based interface in an outpatient setting. The PROMIS
pediatric instruments were sensitive to differences in
clinical status in the largest multi-center study to date of
Gipson et al. Health and Quality of Life Outcomes 2013, 11:30 Page 8 of 9
http://www.hqlo.com/content/11/1/30children with NS in North America to date. Specifically,
we demonstrated that children with active NS had an in-
creased burden in the domains of pain interference, anxiety,
fatigue, and mobility relative to children in remission. The
next step in the PROMIS validation process for children
will be to evaluate self- and parent-proxy report PROMIS
in a longitudinal study and to quantify the minimally im-
portant differences in change in PROMIS scores in patients
with NS.
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